No Data
No Data
Inventiva Announces the Schedule of Publication and Presentation of Its 2024 Full-Year Financial Results
Inventiva Announces The Publication In Biomedicine & Pharmacotherapy Of the Results From A Preclinical Study Demonstrating That Lanifibranor May Reduce Portal Hypertension
TD Cowen Initiates Inventiva(IVA.US) With Buy Rating, Announces Target Price $10
Inventiva Initiated With a Buy at TD Cowen
Express News | Inventiva Shares Are Trading Lower. The Company Announced the Initiation of the Clinical Development Program of Lanifibranor in Japan With the First Japanese Participant Dosed in a Phase 1 Clinical Trial Evaluating the Safety, Tolerability,...
Inventiva And Hepalys Launch Phase 1 Trial Of Lanifibranor In Japan For MASH, Targeting Japanese Market With 32 Participants; Results May Lead To Phase 3; Milestone In Partnership For Expansion In Japan And South Korea